deltatrials
Terminated PHASE2 NCT00911248

PTC299 for Treatment of Neurofibromatosis Type 2

A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2

Sponsor: PTC Therapeutics

Conditions Neurofibromatosis 2
Interventions PTC299
Updated 9 times since 2017 Last updated: Apr 9, 2019 Started: Jul 31, 2009 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

A PHASE2 clinical study on Neurofibromatosis 2, this trial is terminated or withdrawn. The trial is conducted by PTC Therapeutics and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE2

  5. May 2019 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Sep 2018 — May 2019 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Jun 2018 — Sep 2018 [monthly]

    Suspended PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Suspended PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Suspended PHASE2

    First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PTC Therapeutics
  • United States Department of Defense
Data source: PTC Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States